Gregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the completion of the transaction, the executive vice president now directly owns 106,113 shares in the company, valued at $8,051,854.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 1.88% during mid-day trading on Friday, hitting $72.97. The stock had a trading volume of 10,256,506 shares. The stock has a market cap of $95.30 billion, a price-to-earnings ratio of 7.93 and a beta of 1.21. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.10. The firm’s 50-day moving average price is $70.60 and its 200 day moving average price is $68.59.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period last year, the firm earned $3.08 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.80%. Gilead Sciences’s dividend payout ratio is currently 22.58%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Keel Point LLC raised its position in Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 11 shares in the last quarter. West Oak Capital LLC raised its position in Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 32 shares in the last quarter. First Heartland Consultants Inc. raised its position in Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 39 shares in the last quarter. Arrow Financial Corp raised its position in Gilead Sciences by 0.3% in the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after buying an additional 45 shares in the last quarter. Finally, Westover Capital Advisors LLC raised its position in Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 73.99% of the company’s stock.
GILD has been the topic of a number of recent analyst reports. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 target price on the stock in a research report on Tuesday, April 18th. Jefferies Group LLC reiterated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Thursday, April 6th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Thursday, April 6th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target for the company in a report on Tuesday, May 2nd. Finally, Barclays PLC reiterated an “overweight” rating and issued a $85.00 price target (down from $90.00) on shares of Gilead Sciences in a report on Sunday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $80.31.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.